{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-24-000058","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.591744+00:00","generated_at":"2026-06-02T02:26:39.850997+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Praxis Q1 net loss $39.6M; cash $451.2M, positive PRAX-628 data; Essential3 topline H2 2024","bullets":["Net loss $39.6M in Q1 2024 vs $37.5M a year ago; R&D expense $27.0M, G&A $15.3M.","Cash $451.2M at April 30, 2024, from two public offerings ($161.6M Jan, $215.8M Apr); runway into 2027.","PRAX-628 Phase 2a PPR study: 100% response; 80% complete at 15mg, 100% at 45mg; focal onset seizure studies start H2 2024 and H1 2025.","Ulixacaltamide Essential3 trial: >50K pre-screening forms, >7K referrals; topline H2 2024 to support NDA in 2025.","PRAX-562 EMBOLD study in pediatric DEEs: randomization completed; topline results expected Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-24-000058","json":"https://secwatch.observer/filing/0001689548-24-000058.json","markdown":"https://secwatch.observer/filing/0001689548-24-000058.md","text":"https://secwatch.observer/filing/0001689548-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/0001689548-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/prax-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:26:39.850997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fc20779c9400ae1cab3c77a86a38a1527bfdc88","claim":"Praxis Precision Medicines, Inc. reported the first quarter 2024 results: net income $39.6 million.","evidence_excerpt":"Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/0001689548-24-000058-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2024"},{"label":"Net income","value":"$39.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}